Penumbra Inc Stock Price, News & Analysis

Penumbra (NYSE: PEN) reported strong Q1 2025 financial results with total revenue reaching $324.1 million, up 16.3% year-over-year. The company's U.S. Thrombectomy segment showed remarkable growth of 25%, generating revenue of $187.9 million.

Key financial metrics include:

• Operating income of $40.4 million with 12.4% margin
• Net income of $39.2 million with 12.1% margin
• Adjusted EBITDA of $59.6 million with 18.4% margin
• Gross profit of $215.9 million with 66.6% margin

The company maintains its 2025 revenue guidance of $1,340-1,360 million while raising U.S. Thrombectomy growth guidance to 20-21%. Management expects gross margin expansion of at least 100 basis points to over 67% and operating margin of 13-14% for full year 2025.

Penumbra (NYSE: PEN) has scheduled its first quarter 2025 earnings release and conference call for April 23, 2025. The company will release its Q1 2025 financial results after market close, followed by a conference call at 4:30 PM Eastern Time.

Investors and interested parties can access the conference call by dialing (888) 596-4144 with conference ID 6572573, or via webcast through the 'Events and Presentations' section on Penumbra's website. The webcast recording will remain available for a minimum of two weeks after the call.

Penumbra (NYSE: PEN) presented seven new data sets demonstrating the effectiveness of their Computer Assisted Vacuum Thrombectomy (CAVT™) technology at the 2025 Society of Interventional Radiology Annual Meeting. The STRIKE-PE trial showed significant improvements in treating pulmonary embolism, with a 27.8% reduction in right ventricle/left ventricle ratio and 24.5% decrease in pulmonary artery pressures, while maintaining a low adverse event rate under 1%.

The STRIDE study demonstrated high limb salvage rates for lower-extremity acute limb ischemia. The THRIVE study revealed CAVT resulted in 26-46% shorter hospital stays and 46-75% higher home discharge rates compared to traditional treatments. For lower extremity venous thrombus treatment, CAVT showed 17% shorter hospital stays and 40% higher home discharge rates versus anticoagulation alone.

Penumbra Inc (NYSE: PEN) announced that Don Kassing will retire from its board of directors effective April 1, 2025, after 17 years of service. Kassing, who joined the board in 2008 and has served as Presiding Director since 2015, brought significant experience from both academic and corporate sectors.

Kassing's extensive career includes serving as President of San Jose State University (2004-2008), Interim President (2010-2011), and Vice President of Administration and Finance/CFO (1993-2004). His corporate experience spans 11 years, including 8 years at Caleres Inc in merchandising/marketing and operations management, and 3 years in corporate finance at General Motors

Penumbra (NYSE: PEN) reported its Q4 and full-year 2024 financial results. Q4 adjusted revenue reached $321.3 million, up 12.9% year-over-year, while full-year adjusted revenue was $1,200.4 million, increasing 13.4% from 2023. The U.S. market showed strong performance with 21.7% growth in Q4, while international revenues declined by 9.4%.

Q4 net income was $33.7 million with a 10.7% margin, and adjusted EBITDA reached $63.7 million with a 19.8% margin. For the full year 2024, net income was $14.0 million with adjusted EBITDA of $171.0 million.

Looking ahead to 2025, Penumbra projects revenue between $1,340.0-$1,360.0 million, representing 12-14% growth. The company expects U.S. thrombectomy franchise to grow 19-20%, with gross margin expansion of at least 100 basis points to over 67% and operating margin reaching 13-14% of revenue.

Penumbra (NYSE: PEN) has scheduled its fourth quarter and full year 2024 earnings release and conference call for February 18, 2025. The company will issue a press release detailing financial results after market close, followed by a conference call at 4:30 PM Eastern Time.

Investors can access the conference call by dialing (888) 596-4144 with conference ID 5872954, or join via webcast through the 'Events and Presentations' section on Penumbra's website. The webcast recording will remain available for at least two weeks after the call.

Penumbra (NYSE: PEN) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on Monday, January 13, 2025, at 6:00pm ET/3:00pm PT.

Investors and interested parties can access a webcast of the presentation through the 'Events and Presentations' section under the 'Investors' tab on Penumbra's website. The presentation recording will remain available for a minimum of two weeks following the event.

Penumbra (NYSE: PEN) has announced its participation in the upcoming Piper Sandler 36th Annual Healthcare Conference. The company's management team will present on Wednesday, December 4, 2024, at 8:00am ET/5:00am PT.

Interested parties can access a webcast of the presentation through the 'Events and Presentations' section under the 'Investors' tab on Penumbra's website. The webcast recording will remain available for a minimum of two weeks after the event.

Penumbra announced new data showing that patients with intermediate-risk pulmonary embolism (PE) treated with their computer assisted vacuum thrombectomy (CAVT) technology experienced better outcomes compared to other treatments. The study, presented at VIVA 2024, analyzed 2,060 adult patients and revealed that CAVT resulted in 25-35% shorter hospital stays, 25-30% higher rates of home discharge, and 2-3 times fewer complications. The technology also demonstrated potential financial benefits, with hospitals potentially seeing up to a 75% gain in profitable contribution margin if 10% more patients are treated with CAVT compared to anticoagulation alone.